LOTTE Biologics Celebrates Milestone with Songdo Bio Campus Completion Ceremony
LOTTE Biologics Celebrates Completion of Songdo Bio Campus
In an impressive celebration, LOTTE Biologics, led by CEOs James Park and Yooyeol Shin, held a grand ceremony to mark the completion of Plant 1 at the Songdo Bio Campus on November 18, 2026. This inauguration took place at 10:00 a.m. and was attended by approximately 300 distinguished guests from around the world, showcasing the facility's potential to serve as a cornerstone for Korea's biopharmaceutical industry.
A Gathering of Notable Figures
The ceremony was graced by several high-profile attendees, including Dong-bin Shin, Chairman of LOTTE Group, and the Mayor of Incheon, Park Chan-dae. Notably, Prime Minister Han Seong-sook sent a message via video to congratulate the team on this significant achievement. The event featured a series of speeches, including those by CEOs Park and Shin, emphasizing the company's dedication to enhancing the competitiveness of Korea’s bio industry.
The Significance of Plant 1
James Park highlighted the remarkable achievement of completing Plant 1 six months ahead of schedule, a testament to the hard work and dedication of the LOTTE Biologics team. Plant 1 boasts a substantial biopharmaceutical production capacity of 120,000 liters, which positions it as a vital asset for large-scale manufacturing needs. Park emphasized that this facility would act as a strong foundation for growth as they venture deeper into the global market.
Furthermore, Yooyeol Shin elaborated on the strategic importance of this facility. He expressed that the Songdo Bio Campus is more than just a production site; it represents a vital step towards strengthening the capabilities of South Korea's bio industry. Under the vision of becoming a prime Contract Development and Manufacturing Organization (CDMO), LOTTE Biologics aims to build lasting relationships with clients based on trust and quality.
Comments from Leadership
In his speech, Dong-bin Shin stated, "The bio business is the future growth engine for LOTTE Group, critical for leading Korea into the next generation of industries." He expressed hope that Plant 1 would catalyze the growth of the entire industry's competitiveness. The joint vision outlined by LOTTE Group's leadership portrays a commitment to job creation and the cultivation of bio talent.
Infrastructure and Future Plans
The Songdo Bio Campus has been meticulously designed to include not just the manufacturing plant but also a welfare building, utility building, and wastewater treatment facilities, effectively covering all aspects of production and environmental responsibility. With a total area of approximately 99,558 square meters, the site aims to begin full-scale commercial production in 2027, following extensive preparations and validations that are currently underway.
The facility is strategically positioned to link with LOTTE Biologics' existing operations in Syracuse, USA, enabling a more robust global strategy as part of their drive to enhance presence in the CDMO market. This new chapter for LOTTE Biologics signifies a commitment to excellence and innovation in biopharmaceutical production, promising exciting developments for the future.
Conclusion
LOTTE Biologics' completion of Plant 1 at the Songdo Bio Campus is not only a milestone in their operational capabilities but also symbolizes a broader commitment to the growth of the biopharmaceutical sector in Korea. With leadership pledges to prioritize quality and relationships, the future of LOTTE Biologics promises to fortify South Korea's standing in the global biopharmaceutical landscape.